These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32421209)

  • 1. Safe-by-Design: Stakeholders' Perceptions and Expectations of How to Deal with Uncertain Risks of Emerging Biotechnologies in the Netherlands.
    Bouchaut B; Asveld L
    Risk Anal; 2020 Aug; 40(8):1632-1644. PubMed ID: 32421209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responsible Learning About Risks Arising from Emerging Biotechnologies.
    Bouchaut B; Asveld L
    Sci Eng Ethics; 2021 Mar; 27(2):22. PubMed ID: 33779839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uncertainties and uncertain risks of emerging biotechnology applications: A social learning workshop for stakeholder communication.
    Bouchaut B; de Vriend H; Asveld L
    Front Bioeng Biotechnol; 2022; 10():946526. PubMed ID: 36237209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value Conflicts in Designing for Safety: Distinguishing Applications of Safe-by-Design and the Inherent Safety Principles.
    Bouchaut B; Asveld L; Hanefeld U; Vlierboom A
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33670483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modernizing innovation governance to meet policy ambitions through trusted environments.
    Soeteman-Hernández LG; Sutcliffe HR; Sluijters T; van Geuns J; Noorlander CW; Sips AJAM
    NanoImpact; 2021 Jan; 21():100301. PubMed ID: 35559788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe and Sound? Scientists' Understandings of Public Engagement in Emerging Biotechnologies.
    Braun M; Starkbaum J; Dabrock P
    PLoS One; 2015; 10(12):e0145033. PubMed ID: 26660160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adopting Safe-by-Design in Science and Engineering Academia: The Soil May Need Tilling.
    Krouwel SJC; Dierickx ER; Heesterbeek S; Klaassen P
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the Impact of Tensions in Stakeholder Norms on Designing for Value Change: The Case of Biosafety in Industrial Biotechnology.
    Asin-Garcia E; Robaey Z; Kampers LFC; Martins Dos Santos VAP
    Sci Eng Ethics; 2023 Mar; 29(2):9. PubMed ID: 36882674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (Broken) Promises of Sustainable Food and Agriculture through New Biotechnologies: The CRISPR Case.
    Kuiken T; Barrangou R; Grieger K
    CRISPR J; 2021 Feb; 4(1):25-31. PubMed ID: 33570455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Governing biotechnology to provide safety and security and address ethical, legal, and social implications.
    Trump B; Cummings C; Klasa K; Galaitsi S; Linkov I
    Front Genet; 2022; 13():1052371. PubMed ID: 36712887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting Risk Governance of GM Plants: The Need to Consider New and Emerging Gene-Editing Techniques.
    Agapito-Tenfen SZ; Okoli AS; Bernstein MJ; Wikmark OG; Myhr AI
    Front Plant Sci; 2018; 9():1874. PubMed ID: 30622546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing biotechnology with CRISPR/Cas9: recent applications and patent landscape.
    Ferreira R; David F; Nielsen J
    J Ind Microbiol Biotechnol; 2018 Jul; 45(7):467-480. PubMed ID: 29362972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safe(r) by design guidelines for the nanotechnology industry.
    Sánchez Jiménez A; Puelles R; Perez-Fernandez M; Barruetabeña L; Jacobsen NR; Suarez-Merino B; Micheletti C; Manier N; Salieri B; Hischier R; Tsekovska R; Handzhiyski Y; Bouillard J; Oudart Y; Galea KS; Kelly S; Shandilya N; Goede H; Gomez-Cordon J; Jensen KA; van Tongeren M; Apostolova MD; Llopis IR
    NanoImpact; 2022 Jan; 25():100385. PubMed ID: 35559891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Certain new plant breeding techniques and their marketability in the context of EU GMO legislation - recent developments.
    Zimny T; Sowa S; Tyczewska A; Twardowski T
    N Biotechnol; 2019 Jul; 51():49-56. PubMed ID: 30779963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safe-by-Design: from Safety to Responsibility.
    van de Poel I; Robaey Z
    Nanoethics; 2017; 11(3):297-306. PubMed ID: 29238409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Product, not process! Explaining a basic concept in agricultural biotechnologies and food safety.
    Tagliabue G
    Life Sci Soc Policy; 2017 Dec; 13(1):3. PubMed ID: 28255668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Then I went to a hospital abroad": acknowledging implications of stakeholders' differing risk understandings related to use of complementary and alternative medicine in European health care contexts.
    Salamonsen A; Wiesener S
    BMC Complement Altern Med; 2019 Apr; 19(1):93. PubMed ID: 31039772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The commercialization of genome-editing technologies.
    Brinegar K; K Yetisen A; Choi S; Vallillo E; Ruiz-Esparza GU; Prabhakar AM; Khademhosseini A; Yun SH
    Crit Rev Biotechnol; 2017 Nov; 37(7):924-932. PubMed ID: 28100080
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.